Shire Announces FDA Approval of TAKHZYRO™ (lanadelumab-flyo), a First-of-its-Kind mAb Preventive Treatment for Hereditary Angioedema
August 27, 2018 17:14 ET
|
TAKHZYRO
FOR US MEDIA ONLY - In the pivotal study, patients taking TAKHZYRO 300 mg every 2 weeks had an 87% reduction in mean monthly attacks vs. placebo (0.26 vs. 1.97, n=27 vs. n=41) - All secondary...
KalVista Pharmaceuticals Provides Operational Update and Reports Fiscal Fourth Quarter and Full Year Financial Results
July 27, 2017 16:01 ET
|
KalVista Pharmaceuticals, Inc.
– Oral Plasma Kallikrein Inhibitor Portfolio for Treatment of Hereditary Angioedema Continues to Advance – – Intravitreal Diabetic Macular Edema Phase 2 On Track to Initiate in 2017 – CAMBRIDGE,...
KalVista Pharmaceuticals to Recognize HAE Day 2017
May 15, 2017 07:30 ET
|
KalVista Pharmaceuticals, Inc.
CAMBRIDGE, Mass. and PORTON DOWN, United Kingdom, May 15, 2017 (GLOBE NEWSWIRE) -- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery,...
KalVista Pharmaceuticals Appoints Dr. Andreas Maetzel Senior Vice President of Medical
March 09, 2017 07:30 ET
|
KalVista Pharmaceuticals, Inc.
CAMBRIDGE, Mass. and PORTON DOWN, United Kingdom, March 09, 2017 (GLOBE NEWSWIRE) -- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery,...
KalVista Pharmaceuticals Appoints Edward P. Feener, Ph.D. as Chief Scientific Officer
November 29, 2016 07:30 ET
|
KalVista Pharmaceuticals, Inc.
CAMBRIDGE, Mass. and PORTON DOWN, United Kingdom, Nov. 29, 2016 (GLOBE NEWSWIRE) -- KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery,...
KalVista Pharmaceuticals Announces Closing of Merger with Carbylan Therapeutics
November 22, 2016 07:30 ET
|
KalVista Pharmaceuticals Ltd
—Combined company renamed KalVista Pharmaceuticals, Inc., listed on Nasdaq with ticker “KALV” — —Continued focus on development of protease inhibitors with multiple molecules for oral treatment of...